Subsidiary JGL gets tax relief; adjustments cut from Rs 107.89 cr to Rs 42.41 cr

Regulatory & Legal View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹973.90

prior close

₹982.50

announcement price

After-mkt

timing

Nifty Smallcap 250market-0.4%-0.6% vs market

Pharmaceuticals peers, median of 163sector-0.6%-0.4% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Smallcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-0.8

15m

-0.9

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0-0.4-0.6-0.6-0.4

Next day

-1.9-0.9-1.0-0.3-1.6

+0.2-0.4+0.5+0.4-0.2

+0.4+0.1+0.3+0.0+0.4

-0.2+1.1-1.3+0.2-0.4

-0.4+1.2-1.6+1.3-1.7

+0.8+0.9-0.2+0.1+0.7

15d

+4.9+1.2+3.7+0.8+4.1

-0.0+0.2-0.3+0.8-0.8

-8.1+3.2-11.3+1.4-9.5

+10.5+2.1+8.3+5.4+5.0

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jubilant Pharmova's step-down subsidiary Jubilant Generics received an Income Tax Rectification Order for AY 2023-24, reducing total tax adjustments from Rs 107.89 cr to Rs 42.41 cr. JGL also got relief from the Transfer Pricing Officer, restoring tax losses of Rs 65.48 cr. Appeal on merit grounds continues separately before CIT(A).

Likely market impact

Positive for the group; tax adjustments for subsidiary cut by about Rs 65 cr and tax losses of Rs 65.48 cr restored, easing financial burden.